UK drugmaker to partner on COVID-19 vaccines aimed at new variants By Associated Press | February 3, 2021 at 5:54 AM EST - Updated February 3 at 7:49 AM
LONDON (AP) Drugmaker GlaxoSmithKline said Wednesday it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of COVID-19 amid concerns that some mutations are making the virus harder to combat.
GSK plans to invest 150 million euros ($181 million) to support the research of the Tubingen, Germany-based CureVac, which is developing vaccines that use messenger RNA to attack the disease. GSK also said it will help make up to 100 million doses of the company’s existing COVID-19 vaccine candidate this year.
Drugmaker GlaxoSmithKline said Wednesday it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of COVID-19 amid concerns that some mutations are making the virus harder to combat.
GSK plans to invest 150 million euros (USD 181 million) to support the research of the Tubingen, Germany-based CureVac, which is developing vaccines that use messenger RNA to attack the disease. GSK also said it will help make up to 100 million doses of the company s existing COVID-19 vaccine candidate this year. The increase in emerging variants with the potential to reduce the efficacy of first generation COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic, the companies said in a statement.
GSK, CureVac to make vaccines aimed at new COVID-19 variants
By Danica Kirka
LONDON - Drugmaker GlaxoSmithKline said Wednesday it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of COVID-19 amid concerns that some mutations are making the virus harder to combat.
GSK plans to invest 150 million euros ($181 million) to support the research of the Tubingen, Germany-based CureVac, which is developing vaccines that use messenger RNA to attack the disease. GSK also said it will help make up to 100 million doses of the company’s existing COVID-19 vaccine candidate this year. The increase in emerging variants with the potential to reduce the efficacy of first generation COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic,’’ the companies said in a statement.
GSK, CureVac to make COVID-19 vaccines aimed at new variants darientimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from darientimes.com Daily Mail and Mail on Sunday newspapers.
by Staff, wire reports February 3, 2021 .
RESEARCH TRIANGLE PARK Drugmaker GlaxoSmithKline said Wednesday it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of COVID-19 amid concerns that some mutations are making the virus harder to combat.
GSK plans to invest 150 million euros ($181 million) to support the research of the Tubingen, Germany-based CureVac, which is developing vaccines that use messenger RNA to attack the disease. GSK also said it will help make up to 100 million doses of the company’s existing COVID-19 vaccine candidate this year.
“We believe that next generation vaccines will be crucial in the continued fight against COVID-19. This new collaboration builds on our existing relationship with CureVac and means that together, we will combine our scientific expertise in mRNA and vaccine development to advance and accelerate the development of new COVID-19 vaccine candidates,” said Emma Walmsley, GSK’s